Navigation Links
Ibruprofen and other commonly used painkillers for treating inflammation may increase the risk of heart attack

When it comes to the deadly skin cancer melanoma, studying functional tissue rather than cell lines may better provide insight into the disease's development, according to new research from a Howard Hughes Medical Institute predoctoral fellow at Stanford University School of Medicine.

Though multiple genetic alterations are associated with melanoma development, scientists have not been able to establish a direct causal link between these alterations and human cancer growth. Determining whether these mutations have the potential themselves to induce cancer or simply play a supporting role also has been difficult.

To determine the impact of genetic alterations associated with human melanoma, Yakov Chudnovsky; his advisor, Paul Khavari; postdoctoral fellow Amy Adams, and colleagues generated human skin tissue containing cells selectively engineered to express specific mutations found in melanoma. They report their findings in the June 12, 2005, issue of the journal Nature Genetics, offering clues to the oncogenic potency of several genes implicated in the development of melanoma.

Melanoma is the deadliest form of skin cancer, resulting from the malignant transformation of cells called melanocytes. Over the past four decades, the incidence of melanoma has risen 15-fold, a more rapid increase than that of any other cancer.

"The only current treatment is early detection and excision," Chudnovsky said. "But no treatment can substantially enhance patient survival once metastasis has occurred."

To simulate the environment in which melanoma naturally arises, the research team introduced one or more cancer-associated genes into human melanocytes, the pigment-producing cells that normally reside in the deepest layer of the skin. The genetically engineered melanocytes were then combined with keratinocytes, the cells that give skin its structure, to form a sample of human skin that was grafted onto laboratory mice. The mice were observed for
'"/>

Source:http://www.nottingham.ac.uk/


Page: 1 2 3

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Another Look Finds Promising Proteomics Test is Not Biologically Plausible
3. Elephants imitate truck noises, other animals
4. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
5. NJIT Presidential Award winner takes stem cell research another step
6. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
7. NASA links nanobacteria to kidney stones and other diseases
8. Anti cancer virotherapy well tolerated in first human administration, research finds
9. Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer
10. Report that delayed motherhood decreases life expectancy of mouse offspring
11. Rhesus monkeys can assess the visual perspective of others when competing for food
Post Your Comments:
(Date:11/4/2014)... University of Utah engineers developed the first room-temperature fuel ... electricity without needing to ignite the fuel. These new ... off-grid power and sensors. , A study of the ... Society journal ACS Catalysis . , Fuel cells ... a fuel and an oxygen-rich source such as air. ...
(Date:11/4/2014)... 2014   3D ... Fuel3D , a developer of 3D scanning ... totaling $6.4 million (£4 million). This funding builds on the ... year and paves the way for the commercial launch of ... funding round was led by Chimera Partners and will be ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Calif., May 11, 2010 -- Investigators from around the ... Friday, May 7, to share their knowledge of the ... nucleic acids turn off proteins and have been implicated ... other conditions. "The discovery that small RNAs ...
... University have developed a rapid, high-throughput screening method for ... by Munkongdee et al, "Rapid diagnosis of α-thalassemia by ... of The Journal of Molecular Diagnostics . ... defect in the production of a component of hemoglobin. ...
... the 40 th annual meeting of the Society ... research findings on the brain, nervous system, and related ... meeting is the world,s largest source of emerging news ... will discuss how science and society can work together ...
Cached Biology News:Researchers share insights into RNA 2Actress Glenn Close to address stigma of mental illness at world's largest brain science meeting 2Actress Glenn Close to address stigma of mental illness at world's largest brain science meeting 3
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
(Date:11/24/2014)... WASHINGTON , Nov. 24, 2014  Last ... G.K. Butterfield (D-NC) took a bold ... diseases by introducing the OPEN Act. Original co-sponsors ... Hastings (D-FL). The Act will incentivize drug makers ... life-threatening rare diseases and pediatric cancers, which opens ...
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) focuses ... at its mid-Atlantic late-phase research facility, located in ... the idea of closing patient disparities in mind. ... advances," said Continental's CEO, Saleh Stevens . ... cell line of Henrietta Lacks, dubious ethical practices ...
(Date:11/23/2014)... Apiscent Labs, a privately held ... ingredients to the global pharmaceutical and flavor & ... website, Apiscent.com. , The Apiscent.com homepage welcomes visitors ... easy navigation, rotating images and content focused on ... , The company’s work in Pharmaceutical ...
Breaking Biology Technology:Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... QUEBEC CITY, QC, Oct. 2 /PRNewswire-FirstCall/ - AEterna ... company focused on,endocrine therapy and oncology, will announce ... live webcast presentation and conference call hosted by,President ... the outcome,of management,s review of the Company,s pipeline ...
... /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX:NVN) announced today that Gregory M.,McKee, the ... conferences: BioContact Quebec 2007 (Quebec, Canada): ... Mr. McKee is scheduled to present on Thursday, October 4th at ... Salle Laval Room at the Fairmont Le ...
... Pa., Oct. 2 Monitorforhire.com, the,fastest source ... its,service even faster. The company has added ... and respond immediately to work requests via,PDA ... Scott Freedman, president of monitorforhire.com says ...
Cached Biology Technology:AEterna Zentaris Announces Outcome of Management's Strategic Review 2AEterna Zentaris Announces Outcome of Management's Strategic Review 3AEterna Zentaris Announces Outcome of Management's Strategic Review 4Nventa's CEO to present at two upcoming investor conferences 2
... Disruption of the mitochondrial transmembrane ... intracellular events that occur following induction ... Detection Kit utilizes a lipophilic cation, ... activity marker. MitoLight is a mitochondrial ...
... ProteinChip arrays have been developed for ... samples. A variety of ProteinChip chemical ... according to their unique biochemical properties. ... allowing side-by-side sample comparison, and the ...
... VersArray ChipWriter Pro systems are ... proteins, or other biological samples. VersArray ... for uniformity, spot density, and reproducibility ... a variety of substrates. Their modular ...
... Ciphergen's ProteinChip arrays have been developed ... biological samples. A variety of ProteinChip ... proteins according to their unique biochemical ... spots, allowing side-by-side sample comparison, and ...
Biology Products: